The utility of the “Glowing Head” mouse for breast cancer metastasis research
- 66 Downloads
The expression of cellular reporters to label cancer cells, such as green fluorescent protein (GFP) and luciferase, can stimulate immune responses and effect tumor growth. Recently, a mouse model that expresses GFP and luciferase in the anterior pituitary gland was generated to tolerize mice to these proteins; the “Glowing Head” mouse. Mice were obtained from a commercial vendor, bred, and then used for tumor growth and metastasis studies. The transgene expression of luciferase was assessed within tumor-naïve mice as well as mice with mammary tumors or metastases. Tumor-free mice with white fur, compared to black fur, allowed for stronger luciferase transgene expression to be observed in the pituitary, sternum, and femur. Growth of four different luciferase-expressing mouse cancer cell lines readily occurred in the mammary gland. Though sternum expression of the luciferase transgene occurred in cancer-free mice, growth or death of luciferase positive cancer cells in the lung could be observed. Liver metastases seeded by portal vein injections of luciferase positive cancer cell lines were completely distinct from luciferase transgene expression. Though lung and brain metastasis studies have limitations, the Glowing Head mouse can be useful to inhibit immune system rejection of luciferase or GFP expressing cancer cells. This mouse model is most beneficial for studies of mammary tumors and liver metastases.
KeywordsLuciferase IVIS imaging Glowing head mouse PyMT Metastasis
IVIS imaging was performed with instrumentation by the Cancer Mouse Models Shared Resource Core supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059. This work was supported by funds to JCH by the VCU Massey Cancer Center.
Designed experiments; MAA, DCB, JCH, performed cell experiments; MAA, DCB, performed animal experiments; MAA, wrote the manuscript; DCB, JCH, supervised the study; JCH, all authors reviewed and edited the manuscript.
Compliance with ethical standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 14.Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174(10):6477–6489CrossRefGoogle Scholar
- 19.Baklaushev VP, Kilpelainen A, Petkov S, Abakumov MA, Grinenko NF, Yusubalieva GM, Latanova AA, Gubskiy IL, Zabozlaev FG, Starodubova ES, Abakumova TO, Isaguliants MG, Chekhonin VP (2017) Luciferase expression allows bioluminescence imaging but imposes limitations on the orthotopic mouse (4T1) model of breast cancer. Sci Rep 7(1):7715CrossRefGoogle Scholar
- 20.Steinbauer M, Guba M, Cernaianu G, Kohl G, Cetto M, Kunz-Schughart LA, Geissler EK, Falk W, Jauch KW (2003) GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis 20(2):135–141CrossRefGoogle Scholar
- 23.Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff Cherry C, Feigenbaum L, Tuting T, Van Dyke T, Hollingshead M, Merlino G (2014) "Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. PLoS ONE 9(11):e109956CrossRefGoogle Scholar
- 25.Gibby K, You WK, Kadoya K, Helgadottir H, Young LJ, Ellies LG, Chang Y, Cardiff RD, Stallcup WB (2012) Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Breast Cancer Res 14(2):R67CrossRefGoogle Scholar
- 27.Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM (2019) Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol 21(2):238–250CrossRefGoogle Scholar